Humacyte prices $60M registered direct offering of common stock and warrants

Humacyte, Inc.

Raised $60.0M via sale of 28.4M shares and warrants to purchase 28.4M shares at $2.11 per unit.
Warrants exercisable at $2.11, become exercisable 180 days after issuance, expire April 7, 2031.
Offering oversubscribed with institutional investors; expected to close October 8, 2025.
D. Boral Capital acting as exclusive placement agent; fee equal to 5.75% of gross proceeds.
Offered under effective shelf registration statement (File No. 333-290231) declared effective Sept 22, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.